CAR-T SpecialistLymphoma & MyelomaPrivate · Established 2023Changping, Beijing
Beijing GoBroad Hospital Dr. Kai Hu · CAR-T & Haematology
Private specialist oncology hospital in Zhongguancun Life Science Park, Changping. Dr. Kai Hu's team has completed nearly 1,000 CAR-T cases covering lymphoma and myeloma using NMPA-approved commercial products — one of the most experienced commercial CAR-T programmes in northern China, with active access for international patients from 7+ countries. China Care helps you work out whether GoBroad is a suitable option for your specific case before you commit to travelling.
Zhongguancun Life Science Park, Changping District, Beijing — ~45–60 min from Beijing Capital Airport
Quick Facts
Payment
International bank transfer — paid directly to GoBroad. Payment schedule confirmed with hospital's finance team before admission.
Consultation
Remote eligibility review available before travel — Zoom consultation with Dr. Kai Hu
Advance booking
1–2 weeks minimum
Language
English (Dr. Hu and international team) + China Care coordination
Type
Private specialist oncology hospital · CAR-T focus · Established 2023
nearly 1,000
CAR-T cases completed
2
Commercial CAR-T targets available (CD19, BCMA)
7+
Countries, international patients
77
Dedicated department beds
About the Hospital
A Specialist Cancer Center Built Around CAR-T Innovation
Beijing GoBroad Hospital (高博肿瘤医院) opened in July 2023 within Zhongguancun Life Science Park, Changping District. The hospital was purpose-built as a haematology and oncology specialist center, with 77 inpatient beds dedicated to the Lymphoma and Myeloma Department. In February 2024, GoBroad was listed under Beijing Basic Medical Insurance, making it accessible to domestic patients covered under the national insurance scheme — a designation that also validates the hospital's clinical standing for international patients seeking a regulated private institution.
The hospital's clinical programme is led by Dr. Kai Hu, formerly of Peking University People's Hospital, one of China's major haematology centers. Dr. Hu's team has completed nearly 1,000 CAR-T cases, building one of the deepest commercial CAR-T programmes in northern China, administering NMPA-approved CD19-directed products for B-cell lymphomas and leukaemia and BCMA-directed products for multiple myeloma. This case volume reflects Dr. Hu's accumulated clinical experience matching each patient to the appropriate commercial construct and managing the full range of treatment responses.
For international patients, GoBroad offers a structured intake process that differs from China's public tertiary hospitals. Remote eligibility review and a Zoom consultation with Dr. Hu are available before you commit to travel, and private single-occupancy wards with airport pickup are standard. Learn more about how CAR-T cell therapy works in China and what to expect during treatment.
"Some patients have credited us as a leading hospital for bone marrow transplants and CAR-T cell transplants."
Dr. Kai Hu Director, Lymphoma & Myeloma Dept.
About Dr. Kai Hu
Dr. Kai Hu previously served as Director of the Lymphoma Diagnosis and Treatment Center at Peking University People’s Hospital, one of China’s leading haematology centers. He joined GoBroad in 2023 to lead its Lymphoma and Myeloma Department. Dr. Hu communicates directly in English with international patients and is personally involved in all CAR-T protocol decisions for complex or multiply-relapsed cases.
Why Patients Choose GoBroad
What sets GoBroad apart for international patients
Nearly 1,000 Commercial CAR-T Cases
Dr. Hu's team has administered NMPA-approved CD19 and BCMA CAR-T products in nearly 1,000 cases, making this one of northern China's most experienced commercial CAR-T programmes. That case volume supports careful protocol selection and management of treatment responses and toxicity across a wide range of patient profiles.
Remote Eligibility Review Before You Travel
GoBroad reviews your case remotely and arranges a Zoom consultation with Dr. Hu before you commit to travel. You receive a written assessment and cost estimate first. This avoids the need to travel to Beijing before knowing whether treatment is appropriate.
International Patient Infrastructure
Private single-occupancy wards with private bathroom, airport pickup, Zoom consultations, English discharge summaries, and remote follow-up at 1, 3, 6, and 12 months post-treatment. Halal meals can be pre-arranged. GoBroad's international team and China Care coordination together provide end-to-end support in English throughout your stay.
Patient from Kazakhstan — lymphoma, CAR-T treatment at GoBroadInternational patient with GoBroad care teamPatient from Venezuela — haematology treatment at GoBroad
Beyond the Hospital
Why Patients Work With China Care
Finding a hospital's name is easy. Knowing whether it's actually the right one for your situation is much harder — that's where China Care helps.
Most international patients researching GoBroad are unsure whether it's genuinely the right fit for their case, or whether another hospital might serve them better. China Care helps you answer questions like:
CAR-T & Haematology Services Available to International Patients
The Lymphoma and Myeloma Department is most commonly accessed by international patients coordinated through China Care. The department administers NMPA-approved commercial CAR-T products for CD19-positive B-cell malignancies and BCMA-positive multiple myeloma, with Dr. Hu's team drawing on nearly 1,000 completed cases to guide protocol selection for each patient's specific disease profile and treatment history.
Primary Focus
CAR-T: B-Cell Lymphomas & Leukaemia
NMPA-approved commercial CD19-directed CAR-T products for DLBCL, follicular lymphoma, ALL, and other B-cell malignancies.
CD19 CAR-TDLBCLFollicularALL
Primary Focus
CAR-T: Multiple Myeloma
NMPA-approved commercial BCMA-directed CAR-T products. Combined CAR-T + autologous stem cell transplantation (ASCT) protocol developed by Dr. Hu for high-risk myeloma.
BCMA CAR-TMultiple MyelomaASCT
Also Available
Haematopoietic Stem Cell Transplantation
Autologous stem cell transplantation as standalone or in combination with CAR-T. Transplant coordination integrated within the Lymphoma and Myeloma Department.
ASCTCAR-T+ASCTTransplant
Explore your options
Not sure which protocol fits your case?
Hospital Access reviews your diagnosis and prior treatment history, identifies the most appropriate CAR-T construct, and confirms whether GoBroad — or another hospital — is a suitable option, before you commit to travelling.
How China Care Helps You Reach GoBroad — If It's Right for You
Finding a hospital is the easy part. Understanding whether it's the right one for your situation is harder — China Care guides you through that, from initial guidance through to on-the-ground support in Beijing. The steps below outline the typical pathway from initial enquiry to discharge.
Step 1 · Tell Us What You Need
Submit Your Records to China Care
Send complete medical records including pathology reports, imaging (CT/PET-CT/MRI), treatment history including prior therapies and response, and current medications. China Care prepares a bilingual case summary within 1–2 working days.
records review · 1–2 days
Step 2 · Hospital Access
China Care Registers Your Case and Confirms Eligibility
China Care registers your case with GoBroad’s international coordination team and translates your medical records. Dr. Hu’s team reviews your case and confirms preliminary eligibility — which CAR-T construct is appropriate, expected bridging therapy, and manufacturing timeline — helping confirm whether GoBroad, or another hospital, is a suitable option before you commit to travelling. For CAR-T cases, this remote review typically takes 3–5 days. No in-person proxy visit is required before travel.
This is a fixed-fee service, agreed with you upfront.
Hospital Access · fixed fee · remote review 3–5 days
Step 3 · Specialist Consultation
Zoom Consultation With Dr. Kai Hu
Following Hospital Access, China Care arranges a direct Zoom consultation with Dr. Hu before you commit to travel, with a simultaneous interpreter provided. This session covers your diagnosis, proposed protocol, manufacturing timeline, and any questions about procedure-specific risks. CAR-T eligibility requires in-person evaluation and screening on arrival — this Zoom session confirms preliminary suitability.
zoom · interpreter provided
Step 4 · In-Person Consultation & Admission
Travel to Beijing — Admission
Travel to Beijing for your first in-person consultation. The specialist confirms your treatment plan and provides a formal cost estimate at this appointment. A GoBroad driver meets you at Beijing Capital International Airport or Daxing Airport. Admission to a private single-occupancy ward with private bathroom. Dietary requirements including halal meals can be pre-arranged. Payment is made directly to the hospital via international bank transfer or as confirmed by the hospital’s finance team before admission. China Care coordinator available throughout.
private ward · airport pickup
Step 5 · Medical Journey
Discharge & Remote Follow-Up
Upon discharge, complete English-language discharge summary including laboratory results, imaging, and follow-up instructions. Dr. Hu’s team conducts remote monitoring appointments via Zoom at 1, 3, 6, and 12 months post-infusion. China Care remains available as an intermediary for any clinical questions between scheduled follow-ups.
What makes GoBroad different from other CAR-T centers in China?
GoBroad is a private specialist oncology hospital focused exclusively on haematological malignancies, with over 1,000 commercial CAR-T cases completed using NMPA-approved CD19 and BCMA products. Dr. Hu's deep case volume means the team has managed a wide range of treatment responses, toxicity profiles, and re-treatment scenarios. For patients seeking a private, remote-review pathway to commercial CAR-T without a long public-hospital wait, that accumulated experience is a meaningful advantage.
Can GoBroad offer dual-target or investigational CAR-T protocols?
No. As of May 2026, investigator-initiated CAR-T clinical trials in China — including dual-target constructs such as CD19&CD22 or CD20&CD22 — are restricted to public academic hospitals. As a private hospital, GoBroad administers NMPA-approved commercial CD19 and BCMA products only. Patients who have relapsed after a single-target CAR-T and are considering an investigational dual-target trial should be evaluated at one of China's public academic CAR-T centers; China Care can help identify open protocols.
How long is the typical stay for CAR-T treatment?
From admission to discharge, most patients spend 4–6 weeks at GoBroad. This includes lymphodepletion chemotherapy, CAR-T infusion, and the mandatory monitoring period for cytokine release syndrome (CRS) and neurological toxicity. Dr. Hu’s team provides a personalised timeline after reviewing your records.
What languages does the team speak?
Dr. Kai Hu and the core team communicate directly in English. China Care’s coordinator remains available throughout the treatment period, with professional medical interpretation arranged for key consultations. All discharge summaries and follow-up protocols are provided in English.
What follow-up does GoBroad provide after I return home?
Dr. Hu’s team offers remote follow-up consultations via Zoom at 1, 3, 6, and 12 months post-treatment. Blood monitoring protocols are shared with your home haematologist. China Care remains available for coordination for 90 days after discharge.
Still Deciding?
Not every hospital is the right fit for every patient
We'll help you understand whether Beijing GoBroad Hospital — or another hospital in China — may be a better option for your situation.
China Care coordinates your case with Beijing GoBroad Hospital. Treatment costs are quoted directly by the hospital. We never add to, inflate, or mark up the hospital’s quoted treatment cost.
Hospital profile note: This profile is general reference information. China Care does not endorse or guarantee a particular hospital, treatment, appointment, clinical decision, or outcome. Current services, requirements, language support, availability, and clinical suitability should be confirmed directly with the hospital.
We use essential cookies to make this site work. With your permission, we also use analytics cookies to improve it. See our Cookie Policy for details.
